...
首页> 外文期刊>Journal of Thoracic Disease >Patient outcomes post-pulmonary resection for synchronous bone-metastatic non-small cell lung cancer
【24h】

Patient outcomes post-pulmonary resection for synchronous bone-metastatic non-small cell lung cancer

机译:患者成果后肺切除术后同步骨转移性非小细胞肺癌

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Background: The efficacy of curative-intent pulmonary resection for non-small cell lung cancer (NSCLC) patients with certain types of oligometastases, particularly brain and adrenal metastases, has previously been described. We investigated the outcomes of curative-intent pulmonary resection for NSCLC patients with synchronous isolated bone metastases, which have been less clear to date. Methods: We retrospectively reviewed the clinical and pathological records of 41 patients with NSCLC and synchronous isolated bone metastases who underwent radical treatments (surgery and/or chemotherapy and/or radiotherapy) for both their primary tumors and bone metastases at the National Hospital Organization, Hokkaido Cancer Center, between 2008 and 2013. Results: Nine of the 41 patients underwent pulmonary primary tumor resection; the rate of clinical N0–1 disease among these 9 patients (100%) was significantly higher than that among the 32 patients who did not undergo resection (34.4%). The five-year overall survival (OS), progression-free survival (PFS), and disease-free survival (DFS) rates of the nine patients who underwent pulmonary resection were 66.7%, 55.6%, and 44.4%, respectively. On multivariate analysis, the predictors of longer OS among all 41 patients were primary site resection [hazard ratio (HR) =4.18, 95% CI, 1.20–14.6, P=0.025] and epidermal growth factor receptor (EGFR) mutation (HR =3.30, 95% CI, 1.08–10.1, P=0.036). The former was also a predictor of longer PFS (HR =3.75, 95% CI, 1.27–11.0, P=0.016). Conclusions: Patients with clinical N0–1 NSCLC and synchronous isolated bone metastases may achieve longer survival rates following primary lung tumor resection.
机译:背景:先前已经描述了某些类型的寡粒子,特别是脑和肾上腺转移的非小细胞肺癌(NSCLC)患者的疗效肺切除患者的疗效。我们调查了与同步分离骨转移的NSCLC患者的疗意肺切除术的结果,这对迄今为止不太清楚。方法:回顾性地审查了41例NSCLC患者的临床和病理记录,并在国家医院组织,北海道培养了患有自由基治疗(手术和/或化疗和/或放疗)的自由基治疗(手术和/或化疗和/或放射疗法)癌症中心,在2008年至2013年期间。结果:41例患者接受肺部原发性肿瘤切除的九九;这9例患者(100%)中临床N0-1疾病的速率显着高于未接受切除(34.4%)的32例患者中的速率。接受肺切除术后的九个患者的五年整体存活(OS),无病生存(PFS)和无病生存率分别为66.7%,55.6%和44.4%。在多变量分析中,所有41名患者中较长次的预测因子是原发性部位切除[危害比(HR)= 4.18,95%CI,1.20-14.6,P = 0.025]和表皮生长因子受体(EGFR)突变(HR = 3.30,95%CI,1.08-10.1,P = 0.036)。前者也是较长的PFS的预测因子(HR = 3.75,95%CI,1.27-11.0,P = 0.016)。结论:临床NOSCLC和同步分离骨转移患者可能在原发性肺肿瘤切除后达到更长的存活率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号